Generex Biotechnology Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Generex Biotechnology Corporation
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Five Big Pharma Products That Saw Action In India; There’s More To Come
Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.
Pendulum Swings Again: Entresto Patent In India Restored, For Now
Patent pertaining to Novartis’s Entresto re-instated for now in India after a two-judge bench stays a previous order that set aside the grant of the patent. Will that put Indian firms that launched generic versions of the heart failure therapy at risk of infringement in the interim?
Entresto Patent Order Quashed In India, Market Ripe For Action
Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.
- Medical Devices
- Large Molecule
- Other Names / Subsidiaries
- Antigen Express, Inc.
- Grainland Pharmacy LLC
- Hema Diagnostic Systems, LLC
- Medisource Partners
- NuGenerex Distribution Solutions, LLC
- NuGenerex Immuno-Oncology
- Pantheon Medical
- Pantheon Medical – Foot & Ankle
- Regentys Corporation
- Veneto Holdings, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.